Ameriprise
DSGN icon

Ameriprise’s Design Therapeutics DSGN Stock Holding History

Ameriprise’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$978K Buy
67,598
+32,608
+93% +$407K ﹤0.01% 3410
2026
Q1 		$372K Sell
34,990
-123,393
-78% -$1.25M ﹤0.01% 3691
2025
Q4 		$1.49M Buy
+158,383
New +$1.24M ﹤0.01% 3156
2024
Q4 		– Sell
-43,245
Closed -$233K – 4103
2024
Q3 		$233K Sell
43,245
-7,270
-14% -$34.2K ﹤0.01% 3713
2024
Q2 		$169K Hold
50,515
– – ﹤0.01% 3713
2024
Q1 		$204K Sell
50,515
-2,500
-5% -$6.68K ﹤0.01% 3690
2023
Q4 		$140K Buy
+53,015
New +$121K ﹤0.01% 3775

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise's DSGN Position: Q2 2026 in Review

Ameriprise increased its Design Therapeutics (DSGN) stake by 93% in Q2 2026, buying an estimated $407K and bringing the position to 67,598 shares worth $978K. The position accounts for ﹤0.01% of the portfolio, ranked #3410.

Ameriprise first reported a position in DSGN in Q4 2023 and has held it in 7 quarters since. The position peaked at $1.49M in Q4 2025. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Ameriprise held 67,598 shares of Design Therapeutics worth $978K as of Q2 2026.
  • Ameriprise bought 32,608 Design Therapeutics shares in Q2 2026, an estimated $407K.
  • Design Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3410 holding.
  • Ameriprise first reported a position in Design Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • Ameriprise's Design Therapeutics position peaked at $1.49M in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.